Titan Pharmaceuticals Inc
NASDAQ:TTNP

Watchlist Manager
Titan Pharmaceuticals Inc Logo
Titan Pharmaceuticals Inc
NASDAQ:TTNP
Watchlist
Price: 4.61 USD Market Closed
Market Cap: 6.1m USD

EV/EBIT
Enterprise Value to EBIT

-0.7
Current
-0.4
Median
16.8
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-0.7
=
Enterprise Value
3.3m USD
/
EBIT
-4.6m USD
All Countries
Close
EBIT Growth EV/EBIT to Growth
US
Titan Pharmaceuticals Inc
NASDAQ:TTNP
Average EV/EBIT: 1 881.5
Negative Multiple: -0.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.6
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.9
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.9
5%
2.8
UK
AstraZeneca PLC
LSE:AZN
159.4
23%
6.9
CH
Novartis AG
SIX:NOVN
15.2
12%
1.3
US
Merck & Co Inc
NYSE:MRK
11.6
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
11.5
1%
11.5
IE
E
Endo International PLC
LSE:0Y5F
830.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
8%
1.3

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
N/A
2-Years Forward
EV/EBIT
N/A
3-Years Forward
EV/EBIT
N/A